Simulations Plus Newsroom

Simulations Plus Analyst Ratings

BenzingaJul 16 05:31 ET

Buy Rating Affirmed for Simulations Plus Amidst Strong Growth and Strategic Acquisitions

TipRanksJul 4 09:20 ET

Simulations Plus Analyst Ratings

BenzingaJun 28 10:38 ET

Simulations Plus Analyst Ratings

BenzingaJun 13 07:17 ET

Strong Buy Rating for Simulations Plus: A Resilient Market Leader Poised for Sustainable Growth

TipRanksMay 30 06:37 ET

Craig-Hallum Remains a Buy on Simulations Plus (SLP)

TipRanksApr 1 08:41 ET

Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)

TipRanksMar 28 09:25 ET

Craig-Hallum Maintains Buy on Simulations Plus, Raises Price Target to $51

BenzingaJan 4 14:26 ET

Simulations Plus Analyst Ratings

BenzingaJan 4 14:25 ET

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Immunome (IMNM) and Simulations Plus (SLP)

TipRanksJan 4 06:00 ET

Craig-Hallum Reaffirms Their Buy Rating on Simulations Plus (SLP)

TipRanksJan 3 09:06 ET

BTIG Remains a Buy on Simulations Plus (SLP)

TipRanksJan 2 09:44 ET

BTIG Remains a Buy on Simulations Plus (SLP)

TipRanksDec 31, 2023 05:23 ET

Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Celcuity (CELC)

TipRanksNov 13, 2023 09:30 ET

Oppenheimer Adjusts Simulations Plus Price Target to $55 From $67, Maintains Outperform Rating

MT NewswiresOct 26, 2023 09:08 ET

Positive Outlook on Simulations Plus' Future Growth Despite F4Q:23 Revenue Miss: An Analysis of David Larsen's Buy Rating

TipRanksOct 26, 2023 06:53 ET

Positive Growth Projections and Strategic Acquisition Bolster Buy Rating for Simulations Plus: An Analysis by Francois Brisebois

TipRanksOct 24, 2023 23:36 ET

Craig-Hallum Remains a Buy on Simulations Plus (SLP)

TipRanksOct 24, 2023 09:17 ET

Craig-Hallum Remains a Buy on Simulations Plus (SLP)

TipRanksOct 18, 2023 09:27 ET

Analysts Are Bullish on Top Healthcare Stocks: Pliant Therapeutics (PLRX), Simulations Plus (SLP)

TipRanksSep 25, 2023 20:10 ET